1	XAVIER BECERRA
2	Attorney General of California ALEXANDRA M. ALVAREZ
3	Supervising Deputy Attorney General KAROLYN M. WESTFALL
4	Deputy Attorney General State Bar No. 234540
5	600 West Broadway, Suite 1800 San Diego, CA 92101
6	P.O. Box 85266 San Diego, CA 92186-5266
7	Telephone: (619) 738-9465 Facsimile: (619) 645-2061
8	Attorneys for Complainant
9	
10	BEFORE THE MEDICAL BOARD OF CALIFORNIA
11	DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA
12	
13	In the Matter of the Accusation Against: Case No. 800-2017-034874
14	YAROSLAV KUSHNIR, M.D. 709 Third Avenue A C C U S A T I O N
15.	Chula Vista, CA 91910-5803
16	Physician's and Surgeon's Certificate No. G 24238,
17	Respondent.
18	
19	<u>PARTIES</u>
20	1. Christine J. Lally (Complainant) brings this Accusation solely in her official capacity
21	as the Interim Executive Director of the Medical Board of California, Department of Consumer
22	Affairs (Board).
23	2. On or about April 4, 1973, the Medical Board issued Physician's and Surgeon's
24	Certificate No. G 24238 to Yaroslav Kushnir, M.D. (Respondent). The Physician's and
25	Surgeon's Certificate was in full force and effect at all times relevant to the charges brought
26	herein and will expire on February 28, 2022, unless renewed.
27	
28	<i> </i>
	1

ACCUSATION (YAROSLAV KUSHNIR, M.D.) (800-2017-034874)

2

3

4

5

6

7

8

9

10

11

12

13

26

27

28

///

///

unprofessional conduct.

FIRST CAUSE FOR DISCIPLINE

(Gross Negligence)

- 8. Respondent has subjected his Physician's and Surgeon's Certificate No. G 24238 to disciplinary action under sections 2227 and 2234, as defined by section 2234, subdivision (b), of the Code, in that he was grossly negligent in his care and treatment of Patient A,¹ as more particularly alleged hereinafter:
- 9. Between in and around 2004, through in and around 2017, Respondent worked as a psychiatrist at Alvarado Parkway Institute (API). Throughout that time, API received numerous complaints from staff and patients regarding Respondent's disruptive behavior and/or sexually inappropriate comments.
- 10. On or about February 1, 2017, Patient A, a then twenty-one year old female patient was brought to API by her father, seeking emergency psychiatric admission due to her increased suicidal ideation and psychiatric behavior. Patient A had a psychiatric history that included diagnoses of bipolar disorder, occupational defiant disorder, and mood disorder, as well as multiple prior hospitalizations and contacts with law enforcement. During her initial evaluation, Patient A was noted to be floridly psychotic, responding to internal stimuli, making bizarre movements, and rambling incoherently. Patient A admitted to using methamphetamines the day prior, and her urine drug screen was positive for methamphetamine and benzodiazepines. Patient A was admitted to API on a voluntary basis under the psychiatric care of Respondent. On that same date, Respondent evaluated the patient and diagnosed her with schizoaffective disorder, bipolar type, and stimulant dependence (methamphetamine).
- 11. Between on or about February 1, 2017, through on or about May 10, 2017, Respondent evaluated Patient A several times each week. Throughout that time period, Respondent's notes in the patient's chart are short, repetitive, and difficult to read, consist of mostly checked boxes on a preexisting form, and contain no discussion regarding the patient's progress or reference to her treatment plan.

¹ To protect the privacy of the patient involved, the patient's name has not been included in this pleading. Respondent is aware of the identity of the patient referred to herein.

- 12. On or about February 2, 2017, Respondent evaluated Patient A and determined her to be loud, disruptive, and with no insight. The patient informed Respondent that she wanted to go home. Respondent then restarted the patient on her prior medications, which included but was not limited to Cogentin,² trazadone,³ Zyprexa,⁴ Lamictal,⁵ Haldol,⁶ and Clozaril.⁷ Respondent and Patient A both signed a "Patient Consent to Receive Psychotropic Medications" form on that date for these medications, but Respondent did not include any documentation in the patient's chart regarding her capacity to give consent for these medications.
- 13. On or about February 3, 2017, Respondent evaluated Patient A and determined her to be loud, psychotic, and with no insight. The patient again informed Respondent that she wanted to go home.
- 14. On or about February 7, 2017, after K.C., M.S.W. (K.C.) informed Respondent that another patient at API wanted to remain under his care after discharge, Respondent stated, "that's what happens when you sleep with your patients."
- 15. On or about February 7, 2017, after A.M, R.N. (A.M.) asked Respondent if he wanted to update K.C. on another patient she was covering for P.P., M.S.W. (P.P.), Respondent replied,

² Cogentin (brand name for benztropine) is used to treat symptoms of Parkinson's disease or involuntary movements due to the side effects of certain psychiatric drugs (antipsychotics such as chlorpromazine/haloperidol). Benztropine belongs to a class of medication called anticholinergics, and is a dangerous drug pursuant to Business and Professions Code section 4022.

³ Trazodone is an antidepressant that belongs to a group of drugs called selective serotonin reuptake inhibitors. It is used to treat depression, and is a dangerous drug pursuant to Business and Professions Code section 4022.

⁴ Zyprexa (brand name for olanzapine) is an antipsychotic medication used to treat schizophrenia and the symptoms of mood disorders such as bipolar disorder, and is a dangerous drug pursuant to Business and Professions Code section 4022.

⁵ Lamictal (brand name for lamotrigine) is an anticonvulsant medication used to delay mood episodes in adults with bipolar disorder, and is a dangerous drug pursuant to Business and Professions Code section 4022.

⁶ Haldol (brand name for haloperidol) is an antipsychotic medicine used to treat schizophrenia, and is a dangerous drug pursuant to Business and Professions Code section 4022.

⁷ Clozaril (brand name for clozapine) is an antipsychotic medicine used to treat schizophrenia, and is a dangerous drug pursuant to Business and Professions Code section 4022.

"No, [P.P.] is like my wife and [K.C.] is like my mistress. There are certain things that wives do and certain things that mistresses do. My mistress doesn't need to know this."

- 16. On or about February 8, 2017, Respondent evaluated Patient A and determined her to be child-like, with poor judgement, and having no insight. On that same date, Respondent referred the patient for an LPS Conservatorship.⁸
- 17. On or about February 9, 2017, Respondent evaluated Patient A and determined her to be hyper, labile, and with no attention span. Respondent then prescribed the patient Adderall⁹ 10 mg because she was highly agitated and hyperactive. Respondent and Patient A both signed a "Patient Consent to Receive Psychotropic Medications" form on that date for this medication, but Respondent did not include any documentation in the patient's chart regarding her capacity to give consent for this medication.
- 18. On or about February 12, 2017, Patient A submitted a formal request for a change of physician.
- 19. On or about February 13, 2017, Respondent evaluated Patient A and determined her to be labile, hyperactive, with no insight, and preoccupied with discharge home.
- 20. On or about February 14, 2017, Respondent evaluated Patient A and determined her to be gravely disabled, and unable to plan for food, clothing, or shelter for herself.
- 21. On or about February 17, 2017, Respondent evaluated Patient A and determined her to be loud and labile with no insight. On that date, Respondent increased the patient's Adderall prescription to 20 mg.
- 22. On or about February 24, 2017, Respondent evaluated Patient A and determined her to have no insight. Patient A demanded to be discharged and requested another doctor.

⁸ The Mental Health Conservatorship is part of the Lanterman-Petris-Short (LPS) Act 1967. An LPS Conservatorship is the legal term used in California that gives one adult (the conservator) the responsibility for overseeing the comprehensive medical (mental) treatment for an adult (conservatee) who has a serious mental illness. Guidelines for the involuntary mental health treatment are under the California Welfare and Institutions Codes 5200.

⁹ Adderall (brand name for dextroamphetamine and amphetamine) is a Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision (d), and a dangerous drug pursuant to Business and Professions Code section 4022. It is an amphetamine salts used for attention-deficit hyperactivity disorder and narcolepsy.

- 23. On or about February 26, 2017, Patient A informed Respondent again that she wanted another doctor.
- 24. On or about March 1, 2017, Respondent evaluated Patient A and determined her be labile and agitated. On that date, Respondent decreased the patient's Adderall to 10 mg.
- 25. On or about March 4, 2017, Respondent evaluated Patient A and determined her be loud, hyper, labile, and with no insight. On that date, Respondent discontinued the patient's Adderall prescription.
- 26. On or about March 7, 2017, Respondent evaluated Patient A and determined her be loud, with no insight, and preoccupied with discharge. Patient A informed Respondent again that she wanted another doctor.
- 27. On or about March 11, 2017, Patient A submitted another formal request for a change of physician.
- 28. On or about March 13, 2017, Patient A submitted to a psychological evaluation and testing at API, which revealed a finding of severe intellectual impairment.
- 29. On or about March 13, 2017, Respondent attended a meeting with API executive staff regarding complaints they had received about his inappropriate comments towards staff. During this meeting, Respondent did not deny telling a staff member one week earlier that he thinks API should not hire women with children.
- 30. Sometime between on or about February 1, 2017, and on or about March 16, 2017, Respondent asked Patient A for a hug at the conclusion of his evaluation. After doing so, Respondent then turned to a female employee, F.Z., and asked her to turn around so he and Patient A could "make out." Patient A was visibly uncomfortable by the comment and left the room. Later that day, Respondent patted his knee and told F.Z. to come sit on his lap.
- 31. On or about March 28, 2017, Respondent agreed to a corrective action plan with API executive staff.
- 32. On or about May 9, 2017, Patient A reported to her assigned social worker that she was no longer comfortable with receiving treatment from Respondent and claimed he had made multiple inappropriate comments and gestures towards her.

THIRD CAUSE FOR DISCIPLINE

(Failure to Maintain Adequate and Accurate Records)

39. Respondent has further subjected his Physician's and Surgeon's Certificate No. G 24238 to disciplinary action under sections 2227 and 2234, as defined by section 2266, of the Code, in that Respondent failed to maintain adequate and accurate records regarding his care and treatment of Patient A, as more particularly alleged in paragraphs 8 through 37, above, which are hereby incorporated by reference and realleged as if fully set forth herein.

FOURTH CAUSE FOR DISCIPLINE

(Incompetence)

40. Respondent has further subjected his Physician's and Surgeon's Certificate No. G 24238 to disciplinary action under sections 2227 and 2234, as defined by section 2234, subdivision (d), of the Code, in that he has demonstrated incompetence in his care and treatment of Patient A, as more particularly alleged in paragraphs 8 through 37, above, which are hereby incorporated by reference and re-alleged as if fully set forth herein.

FIFTH CAUSE FOR DISCIPLINE

(Unprofessional Conduct)

41. Respondent has further subjected his Physician's and Surgeon's Certificate No. G 24238 to disciplinary action under sections 2227 and 2234, as defined by section 2234, of the Code, in that he has engaged in conduct which breaches the rules or ethical code of the medical profession, or conduct which is unbecoming a member in good standing of the medical profession, and which demonstrates an unfitness to practice medicine, as more particularly alleged in paragraphs 8 through 37, above, which are hereby incorporated by reference and realleged as if fully set forth herein.

24 | /// 25 | /// 26 | /// 27 | ///

///

PRAYER 1 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, 2 and that following the hearing, the Medical Board of California issue a decision: 3 Revoking or suspending Physician's and Surgeon's Certificate No. G 24238, issued 1. 4 to Respondent, Yaroslav Kushnir, M.D.; 5 Revoking, suspending or denying approval of Respondent, Yaroslav Kushnir, M.D.'s 2. 6 7 authority to supervise physician assistants and advanced practice nurses; Ordering Respondent, Yaroslav Kushnir, M.D., if placed on probation, to pay the . 3. 8 Board the costs of probation monitoring; and 9 Taking such other and further action as deemed necessary and proper. 10 11 MAY 2 8 2020 12 DATED: 13 Interim Executive Di Medical Board of California Department of Consumer Affairs 14 State of California 15 Complainant 16 17 SD2020300287 82288524.docx 18 19 20 21 22 23 24 25 26 27 28